Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DiaKine Therapeutics and AdPharma have entered into an agreement to develop a pipeline of drugs aimed at reversing diabetes.
Subscribe to our email newsletter
DiaKine said that the partnership would approach treating diabetes in a new way by preserving or restoring the patient's own insulin-producing cells.
The first drug in the pipeline is Lisofylline (LSF), an immune modulating compound that has reversed type 1 diabetes in mice in combination with another agent. LSF is a synthetic small molecule, with anti-inflammatory properties, that blocks autoimmune damage to insulin-producing cells.
“Our arrangement with AdPharma accelerates our drug development process, and as a partner, provides a creative and non-dilutive means to advance our pipeline,” said Keith Ignotz, CEO and president of DiaKine.
DiaKine plans to take its immune modulator, LSF, to arrest diabetes and restore insulin production into a phase II proof of principal clinical trial and then collaborate or license it to a large pharmaceutical company for further development and commercialization.